Health Canada okays GSK unit's monthly HIV injection

by Reuters
Monday, 23 March 2020 10:17 GMT

DATE IMPORTED:05 March, 2019A digitally colorized scanning electron microscopic (SEM) image depicts a single, red colored H9-T cell that had been infected by numerous, spheroid shaped, mustard colored human immunodeficiency virus (HIV) particles attached to the cell's surface membrane, as seen in this 2012 image obtained from the National Institute of Allergy and Infectious Diseases (NIAID) located in Bethesda, Maryland, U.S., on March 5, 2019. Courtesy National Institute of Allergy and Infectious Diseases (NIAID)/Handout via REUTERS

Image Caption and Rights Information

Canada's healthcare regulator has approved GlaxoSmithKline's Cabenuva, which suppresses the virus that causes AIDS

March 20 (Reuters) - GlaxoSmithKline’s HIV treatments division said on Friday that Canada’s healthcare regulator has approved its long-acting HIV injection, in a major win for the British drugmaker after a U.S. rejection late last year.

GSK's ViiV Healthcare said that Health Canada had given the green light to Cabenuva, a monthly injection to suppress the virus that causes AIDS and is aimed as an alternative to daily pills. (bit.ly/3aatmo8)

(Reporting by Pushkala Aripaka in Bengaluru; Editing by Vinay Dwivedi)

Our Standards: The Thomson Reuters Trust Principles.